化学发光免疫分析技术测定游离及总前列腺特异抗原比值的临床应用

Chemiluminescence immuneanalysis techniquein the evaluation of theratiooffreeprostate specific antigen to total prostate specific antigen

采用美国DPC公司的f -PSA、t -PSA试剂和IMMULITE全自动化学发光免疫分析仪检测 6 5例健康人、77例前列腺增生和 42例前列腺癌患者的f -PSA和t -PSA ,并求得f -PSA/t -PSA比值。结果显示 :单独以t -PSA >2 .85 μg/L或f -PSA >0 .6 3μg/L作为对PCa的诊断指标 ,其特异性和阳性预测值分别为 5 3 .5 %、5 0 .9%和 5 5 .8%、5 1.0 % ,而以DPC公司推荐的f -PSA/t -PSA比值 <0 .11作为对PCa的诊断指标 ,其特异性和阳性预测值分别达 88.7%、81.3 % ,显著高于t -PSA和f -PSA(P <0 .0 1)。说明f-PSA/t -PSA比值结合临床情况和影像学检查 ,可大大提高PSA对PCa诊断的特异性 。

Thef-PSAandt-PSAkit (producedbyAmericanDPCcompany)andanIMMULITEtotalauto maticchemiluminescenceimmuneanalysistechniquewereusedtodetectthefreeprostatespecificantigen (f-PSA) andthetotalprostatespecificantigen (t -PSA)andtocaculatetheratiooff-PSAtot -PSA .Resultsshowedthat whent-PSA >2 .85μg/Lorf-PSA >0 .63μg/Lwereusedasanindextodiagnoseprostatecancer (PCa)individ ually ,theirspecificityandpositiveforcastingvaluewere 53.5% ,50 .9%and 55.8% ,51.0 % ,respectively .How ever ,whentheratiooff-PSAtot-PSA <0 .11(recommendedbytheDPCcompany)wereusedasanindextodi agnosePCa ,itsspecificityandpositiveforecastingvaluereached 88.7%and 81.3% ,respectively .Thiswassignifi cantlyhigherthanthatoft-PSAandf-PSA ,respectively ,(P <0 .0 1) .Thisstudysuggeststhattheratiooff - PSAtot -PSA ,incombinationwiththeclinicalconditionandimageexaminationcangreatlyincreasethespecificity ofPSAindiagnosingPCasothatitcansupportanearlydiagnosisofPCa .